Bharat Parenterals Limited

Bharat Parenterals Limited (BPL) is a pharmaceutical company established in 1992, headquartered in Vadodara, Gujarat, India. The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. BPL is a publicly listed entity with the Corporate Identification Number (CIN) L24231GJ1992PLC018237. As of December 2025, the company reported a workforce of 396 employees. In the fiscal year ending March 2025, BPL reported a net income of INR 82.3 million, a significant increase from INR 12.8 million in the same period the previous year. The company's official website is www.bplindia.in.

BPL operates a WHO-GMP accredited manufacturing facility located in Vadodara, Gujarat. The plant spans over 30,000 square feet and is equipped to produce a diverse range of pharmaceutical formulations, including tablets, capsules, oral liquids, eye drops, ointments, lotions, and creams. The facility is designed to handle large batch sizes, ensuring scalability and efficiency in production.

The leadership team at BPL is headed by Managing Director Mr. Bharat Kumar R. Desai, who has been with the company since its inception in 1992. Other key executives include Mr. Hemang Jayendrabhai Shah, serving as Executive Director since 2010, and Mr. Shaileshkumar Gabhawala, an Independent Non-Executive Director since 2017. The Board also includes Independent Non-Executive Directors such as Ms. Zankhana Bimalkumar Sheth and Mr. Mukeshbhai Jivrajbhai Patel.

BPL has made significant strides in obtaining regulatory approvals for its products in various international markets. The company holds WHO-GMP certification for its manufacturing facility, which is a prerequisite for exporting to numerous countries. Additionally, BPL has been recognized as a 2 Star Export House, indicating its established presence in the export market. While specific details regarding approvals from the US FDA, EMA, MHRA, and TGA are not publicly disclosed, the company's adherence to WHO-GMP standards suggests a commitment to meeting international regulatory requirements.

BPL has expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's WHO-GMP certification facilitates access to these regions, as it is recognized by the World Health Organization and many national regulatory authorities. BPL's diverse product portfolio, encompassing over 800 products across 20 therapeutic categories, positions it well to cater to the varied healthcare needs of these markets.

BPL's export data indicates a concentration in specific therapeutic categories, with Antiviral & HIV Medications accounting for 53.6% of exports, Antibiotics at 25.9%, and Combination Drugs at 9.2%. This focus suggests a strategic emphasis on high-demand therapeutic areas. However, the company's portfolio concentration, with the top five products comprising 88.6% of total exports, indicates potential risks associated with over-reliance on a limited product range. Diversifying its product offerings could mitigate these risks and enhance market resilience.

Specific details regarding BPL's FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available. The company's adherence to WHO-GMP standards and its status as a 2 Star Export House suggest a commitment to meeting international regulatory standards, which may facilitate market access in the United States. However, without explicit FDA approvals, the company's ability to market products in the U.S. remains uncertain.

BPL's manufacturing facility holds WHO-GMP certification, indicating compliance with international manufacturing standards. This certification is essential for exporting pharmaceutical products to various countries and reflects the company's commitment to quality and regulatory compliance. While specific details regarding EU GMP certificates and EDQM status are not publicly disclosed, the WHO-GMP certification suggests that BPL's manufacturing practices align with international quality standards.

BPL operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility is licensed by the CDSCO, ensuring compliance with national standards for pharmaceutical manufacturing. Additionally, BPL holds export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its export activities. The company's adherence to these regulatory requirements underscores its commitment to maintaining high-quality manufacturing practices.

As of March 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to BPL by regulatory authorities. The absence of such actions suggests that the company maintains a positive compliance record with regulatory bodies. However, without access to detailed inspection histories, a comprehensive assessment of the company's regulatory standing cannot be made.

BPL operates in a competitive pharmaceutical market, facing competition from both domestic and international companies. While specific market share data is not publicly available, the company's focus on high-demand therapeutic areas such as Antiviral & HIV Medications and Antibiotics positions it in segments with significant competition. To enhance its competitive standing, BPL may consider diversifying its product portfolio and expanding its presence in emerging markets.

BPL's key differentiators include its WHO-GMP accredited manufacturing facility, a diverse product portfolio spanning over 800 products across 20 therapeutic categories, and a strong export presence as a 2 Star Export House. These factors collectively contribute to the company's ability to meet a wide range of healthcare needs and maintain a competitive edge in the pharmaceutical industry.

BPL's current strategic direction focuses on the manufacturing of generic pharmaceutical formulations, with an emphasis on high-demand therapeutic areas such as Antiviral & HIV Medications and Antibiotics. The company's future outlook includes expanding its product portfolio, enhancing operational efficiency, and increasing its presence in both regulated and emerging markets. By leveraging its manufacturing capabilities and regulatory certifications, BPL aims to strengthen its position in the global pharmaceutical market.

BPL has demonstrated a consistent track record in pharmaceutical manufacturing, with a reported export value of $5.2 million USD across 209 shipments from 2022 to 2026. The company's adherence to WHO-GMP standards and its status as a 2 Star Export House reflect its commitment to quality and reliability. However, the high concentration of exports in a few products suggests potential risks associated with over-reliance on a limited product range. Diversifying its product offerings could enhance the company's resilience and appeal to a broader customer base.

Importers should verify the following certifications when considering BPL as a supplier:

• WHO-GMP Certification: Confirms compliance with international manufacturing standards.

• ISO 9001:2015 Certification: Indicates adherence to quality management systems.

• ISO 10002:2014 Certification: Demonstrates commitment to customer satisfaction and complaint handling.

These certifications can typically be verified through the company's official website or by contacting the relevant certifying bodies.

When conducting due diligence on BPL, consider the following steps:

• Verify Regulatory Compliance: Confirm WHO-GMP, ISO 9001:2015, and ISO 10002:2014 certifications.

• Assess Financial Health: Review financial statements for profitability trends and operational efficiency.

• Evaluate Product Portfolio: Analyze the diversity and market demand of the company's product offerings.

• Examine Export Records: Assess export volumes and consistency to gauge reliability.

• Review Regulatory History: Check for any past regulatory actions or compliance issues.

Red flags to watch for include declining profitability, over-reliance on a limited product range, and any history of regulatory non-compliance. Recommended pre-order checks involve verifying certifications, assessing financial health, and evaluating the company's track record in meeting delivery commitments.